Background : Gallbladder carcinoma is a relatively rare malignancy with an extremely poor prognosis. The pathologic staging of gallbladder carcinoma is a key determinant of the patient’s prognosis and the treatment options. However, we have often en...
Background : Gallbladder carcinoma is a relatively rare malignancy with an extremely poor prognosis. The pathologic staging of gallbladder carcinoma is a key determinant of the patient’s prognosis and the treatment options. However, we have often encountered patients in whom the course of their disease differed substantially from what would be predicted based on their clinical staging, which highlights the needs to consider additional predictive factors. Gallbladder carcinoma occurs more frequently in women than men, yet expression of the estrogen receptor(ER) family and progesteron(PR) have not been studied. We applied an immunohistochemical technique to examine the expression of ERα , ERβ and PR in radically resected gallbladder carcinoma tissues and then compared their expression status with several clinicopathological factors.Methods: We immunohistochemically investigated 30 formalin-fixed, paraffin-embedded specimens of gallbladder adenocarcinoma tissues using ERα , ERβ and PR antibodies. The expression of ERα, ERβ and PR were compared using the Chi-square test. Survival was analyzed using the Kaplan-Meier method, verified by the Log-Rank test.Results: The results indicated that adenocarcinoma of gallbladder are both negative for ERα and PR, irrespective of histologic grade, TNM stage and sex. However, twenty-two of 30 cases (73.3%) were confirmed positive for ERβ, which was significantly correlated with poor differentiated tumor grade. Overall survival rates of ERβ-positive and negative patients were 77.3% and 37.5%, respectively (p=0.034). In multivariate analysis, only ERβ was statistically significant (p=0.033).Conclusion: Evaluation of ERβ expression in gallbladder carcinoma may be an important factor in identifying a poor prognostic group of gallbladder carcinoma.